Literature DB >> 23749933

Different impact of IL10 haplotype on prognosis in lung squamous cell carcinoma and adenocarcinoma.

Yaw-Cheng Wang1, Wen-Wei Sung, Lee Wang, Ya-Wen Cheng, Chih-Yi Chen, Tzu-Chin Wu, Shwn-Huey Shieh, Huei Lee.   

Abstract

BACKGROUND: Polymorphisms (1082A>G, - 819C>T, and -592G>A) in the interleukin-10 (IL10) promoter are associated with its transcriptional activity. IL10 induction by cigarette smoking plays a role in smoking-related lung tumor progression. We therefore expected to find a difference in impact of IL10 haplotypes on overall survival (OS) and relapse-free survival (RFS) between squamous cell carcinomas (SCC) and adenocarcinomas (ADC) of lung.
MATERIALS AND METHODS: Normal lung tissues adjacent to resected tumors from 439 lung cancer patients were collected to determine IL10 haplotypes (ATA and non-ATA) by direct sequencing and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Kaplan-Meier and multivariate Cox regression models were used to assess the impact of IL10 haplotype on OS and RFS. Resluts: The non-ATA haplotype was more prevalent in patients with nodal metastatic tumors (N1 and N2) than in those with non-nodal metastatic tumors (N0). This observation was only made for patients with SCC and not ADC. Patients with SCC with the non-ATA haplotype had poorer OS and RFS when compared to those with the ATA haplotype, whereas IL10 haplotype was not associated with the clinical outcome of patients with ADC.
CONCLUSION: The IL10 haplotype may independently predict survival and relapse in patients with surgically resected SCC, but not ADC.

Entities:  

Keywords:  IL10; adenocarcinoma; haplotype; lung cancer; prognosis; squamous cell carcinoma

Mesh:

Substances:

Year:  2013        PMID: 23749933

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Interleukin-10 promoter polymorphism and susceptibility to lung cancer: a systematic review and meta-analysis.

Authors:  Xiong Lan; Tian Lan; Qin Faxiang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients.

Authors:  Nicholas T Woods; Alvaro N Monteiro; Zachary J Thompson; Ernest K Amankwah; Nina Naas; Eric B Haura; Amer A Beg; Matthew B Schabath
Journal:  Mol Carcinog       Date:  2015-01-18       Impact factor: 4.784

3.  FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1.

Authors:  Myungshin Kim; Jiyeon Kim; Jung Rok Kim; Eunhee Han; Joonhong Park; Jihyang Lim; Yonggoo Kim; Kyungja Han; Hee-Je Kim; Woo-Sung Min; Bin Cho
Journal:  Mol Biol Rep       Date:  2014-10-07       Impact factor: 2.316

4.  Association of TNFα-308, IFNγ+874, and IL10-1082 gene polymorphisms and the risk of non-small cell lung cancer in the population of the South Indian state of Telangana.

Authors:  Vidyullatha Peddireddy; Siva Prasad Badabagni; Shehnaz Sulthana; Venkata Karunakar Kolla; Sandhya Devi Gundimeda; Hemaprasad Mundluru
Journal:  Int J Clin Oncol       Date:  2016-04-16       Impact factor: 3.402

5.  The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma.

Authors:  Jau-Chung Hwang; Wen-Wei Sung; Hung-Pin Tu; Kun-Chou Hsieh; Chung-Min Yeh; Chih-Jung Chen; Hui-Chun Tai; Chao-Tien Hsu; Grace S Shieh; Jan-Gowth Chang; Kun-Tu Yeh; Ta-Chih Liu
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.